BLUE
Companies
NASDAQ
Bluebird Bio, Inc.
Health Care
$4.97
-$3.37 (-40.41%)
Price Chart
Overview
About BLUE
we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.
Market Cap
$174.4M
Volume
7.4M
Avg. Volume
3.0M
P/E Ratio
-7.646154
Dividend Yield
0.00%
Employees
528.0
Company Information
Latest News for BLUE
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
March 31, 2025
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
February 21, 2025
FDA greenlights first gene-editing treatment, Casgevy, for sickle cell disease
December 8, 2023
Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates
May 14, 2025
Risk & Correlation Analysis
Market Correlation
2.26
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, BLUE shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$174.4M
Volume7.4M
P/E Ratio-7.65
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 15, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025